Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial

•Phase II analysis of the efficacy and safety of afatinib therapy for HER2m + NSCLC.•No patient achieved an overall response, and no clinical benefit was demonstrated.•The trial was prematurely discontinued due to poor efficacy and slow recruitment.